Residual mediastinal widening following therapy in Hodgkin's disease.

Abstract:

:The chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed planned treatment and had no evidence of persisting extramediastinum disease at restaging. Thirty-nine cases (38 per cent) showed residual mediastinal widening at the end of therapy (minimal changes in nine and measurable changes in 30 cases). Neither presenting features nor treatment modality correlated with residual mediastinal mass on chest X-ray. The isolated intrathoracic relapse rate was 11 per cent for patients with normal mediastinum following therapy, as compared with 20.5 per cent for those with residual widening; this difference did not reach statistical significance (p = 0.3). The persistence of mediastinal abnormalities was associated with a trend towards a higher risk of intrathoracic relapse for patients with initial bulky disease (p less than 0.05) and for those with B symptoms (p = 0.07). Using thoracic CT scan for restaging (56 patients), the residual mediastinum rate rose to 70 per cent; the predictability of local relapse with this procedure was not greater than with conventional X-ray study.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Orlandi E,Lazzarino M,Brusamolino E,Caldera D,Morra E,Dore R,Di Giulio G,Bernasconi C

doi

10.1002/hon.2900080303

subject

Has Abstract

pub_date

1990-05-01 00:00:00

pages

125-31

issue

3

eissn

0278-0232

issn

1099-1069

journal_volume

8

pub_type

杂志文章
  • In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions.

    abstract::Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2724

    authors: Sonigo C,Bajeux J,Boubaya M,Eustache F,Sifer C,Lévy V,Grynberg M,Sermondade N

    更新日期:2020-10-01 00:00:00

  • Intensified therapy followed by autologous stem-cell transplantation (ASCT) versus conventional therapy as first-line treatment of follicular lymphoma: a meta-analysis.

    abstract::There are two different international standards for the treatment of follicular lymphoma (FL): intensified therapy followed by autologous stem-cell transplantation (ASCT) and conventional therapy in the first-line setting. However, their role remains unclear. Our aim was to define the treatment effect of intensified t...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析

    doi:10.1002/hon.2015

    authors: Wang B,Ren C,Zhang W,Ma X,Xia B,Sheng Z

    更新日期:2013-03-01 00:00:00

  • Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation.

    abstract::Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2050

    authors: Bezinelli LM,de Paula Eduardo F,da Graça Lopes RM,Biazevic MG,de Paula Eduardo C,Correa L,Hamerschlak N,Michel-Crosato E

    更新日期:2014-03-01 00:00:00

  • Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia.

    abstract::Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070605

    authors: Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

    更新日期:1989-11-01 00:00:00

  • Large cell lymphoma with initial presentation in the bone marrow.

    abstract::This report describes 14 cases of large cell lymphoma with initial presentation as marrow involvement in the absence of peripheral lymphadenopathy. The disease affected mainly the middle-aged and elderly, with male predominance. Most patients presented with swinging fever and peripheral blood cytopenia. Reactive hemop...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100504

    authors: Wong KF,Chan JK,Ng CS,Chu YC,Li LP,Chan CH

    更新日期:1992-09-01 00:00:00

  • Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests.

    abstract::Peripheral blood progenitor cells used during high dose treatments for malignancy may be contaminated with tumour cells that could later contribute to recurrence. CD34+ selected harvests still contain tumour cells and an additional negative selection may be capable of reducing this contamination. We have assessed a tw...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/1099-1069(200009)18:3<111::aid-hon657>3.0.

    authors: Davies FE,Rawstron AC,Pratt G,Coupe R,Clarke D,Lubenko A,Short K,Perren TJ,Selby PJ,Maclennan S,Major K,Woodhead V,Robinson F,Child JA,Smith GM,Johnson PW,Morgan GJ

    更新日期:2000-09-01 00:00:00

  • Role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating breast mucosa-associated lymphoid tissue lymphoma: A case series.

    abstract::Mucosa-associated lymphatic tissue (MALT) lymphoma of the breast is an extremely rare disease; its pathogenesis is not clear because of the rarity of disease, and the best diagnostic method has yet to be established. The metabolic behavior of this lymphoma is not still clear because only a few case reports are present...

    journal_title:Hematological oncology

    pub_type:

    doi:10.1002/hon.2376

    authors: Albano D,Bosio G,Orlando E,Bertagna F

    更新日期:2017-12-01 00:00:00

  • Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.

    abstract::Implementation of cytarabine into induction therapy became standard of care for younger patients with mantle cell lymphoma (MCL). On the basis of its beneficial impact, many centers incorporated cytarabine at lower doses also into first-line treatments of elderly patients. We conducted a multicenter observational stud...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2483

    authors: Klener P,Fronkova E,Belada D,Forsterova K,Pytlik R,Kalinova M,Simkovic M,Salek D,Mocikova H,Prochazka V,Blahovcova P,Janikova A,Markova J,Obr A,Berkova A,Kubinyi J,Vaskova M,Mejstrikova E,Campr V,Jaksa R,Kodet R,

    更新日期:2018-02-01 00:00:00

  • Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.

    abstract::Mantle cell lymphoma (MCL) is a lymphoproliferative disorder characterized by the t(11;14)(q13;q32) CCND1/IGH translocation. This lymphoma is however extremely heterogeneous in terms of molecular alterations. Moreover, the course of the disease can vary greatly between indolent forms with slow progression and aggressi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/hon.2750

    authors: Le Bris Y,Magrangeas F,Moreau A,Chiron D,Guérin-Charbonnel C,Theisen O,Pichon O,Canioni D,Burroni B,Maisonneuve H,Thieblemont C,Oberic L,Gyan E,Pellat-Deceunynck C,Hermine O,Delfau-Larue MH,Tessoulin B,Béné MC,Minviel

    更新日期:2020-10-01 00:00:00

  • Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.

    abstract::The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the effectiveness of pomalidomide after failure of lenalidomide and (or) bortezomib. We search...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2192

    authors: Sheng Z,Liu G

    更新日期:2016-06-01 00:00:00

  • Characterization of myeloid leukemias with monoclonal antibodies 3C5 and MY9.

    abstract::The expression of two membrane antigens identified by the monoclonal antibodies (McAb) My9 and 3C5 has been investigated in cells from 80 acute leukemias. My9 was positive in the blasts of 33 out of the 38 (87 per cent) cases of acute myeloid leukemia (AML) tested, regardless of FAB subtype, and in 13 of 18 (72 per ce...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030306

    authors: Matutes E,Rodriguez B,Polli N,Tavares de Castro J,Parreira A,Andrews C,Griffin JD,Tindle RW,Catovsky D

    更新日期:1985-07-01 00:00:00

  • Pediatric non-Hodgkin's lymphoma abdominal presentations: a comparative study between two treatment regimens at the National Cancer Institute Cairo.

    abstract::Abdominal presentations of pediatric NHL are rarely amenable to complete surgical resection. Chemotherapy is the hallmark of treatment for pediatric NHL. Treatment of various types of this disease including intra-abdominal NHL in children with various protocols have not exceeded 54 per cent two-year disease-free survi...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2900090414

    authors: Abdel Hadi SS,el Taneer OM,Hussein MH,el Haddad A,el Badawi S,Mokhtar N,Hamza MR,el Mawla NG

    更新日期:1991-07-01 00:00:00

  • Plasma concentration of itraconazole in patients receiving chemotherapy for hematological malignancies: the effect of famotidine on the absorption of itraconazole.

    abstract::Fungal infection is a serious complication in immunocompromised patients, especially those with neutropenia. Itraconazole (ITZ) is expected to be an effective prophylactic agent for fungal infection because it has more activity against Aspergillus species than fluconazole and it is less toxic than amphotericin-B. Howe...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/(sici)1099-1069(1998030)16:1<33::aid-hon62

    authors: Kanda Y,Kami M,Matsuyama T,Mitani K,Chiba S,Yazaki Y,Hirai H

    更新日期:1998-03-01 00:00:00

  • A monoclonal antibody 1A6 to T-cell recognizes a common antigen expressed on lymphocytes from normal and leukemic patients, and inhibits NK cell activity.

    abstract::A new monoclonal antibody (MAB), IA61gG2a, has been derived from Balb/c mice after immunization with T-cell chronic lymphocytic leukemia (T-CLL). This monoclonal antibody, 1A6 was tested on normal human peripheral blood cells, leukemia patients' cells and leukemia-lymphoma cell lines. The results demonstrated that thi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070306

    authors: Togashi H,Ghoneum M,Takasugi M,Kasai K,Mugishima H,Billing R,Terasaki PI

    更新日期:1989-05-01 00:00:00

  • Clinical significance and prognosis of MYC translocation in diffuse large B-cell lymphoma.

    abstract::Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.991

    authors: Zhang HW,Chen ZW,Li SH,Bai W,Cheng NL,Wang JF

    更新日期:2011-12-01 00:00:00

  • On point in primary CNS lymphoma.

    abstract::Primary CNS lymphoma (PCNSL) is an aggressive brain tumor that represents a significant challenge both to elucidate its biological pathogenesis as well as to develop definitive precision medicines with minimal collateral toxicity. We highlight the key issues in diagnosis and treatment and focus on emerging technologie...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2761

    authors: Tsang M,Cleveland J,Rubenstein JL

    更新日期:2020-12-01 00:00:00

  • Lymphomas and thyroid: Bridging the gap.

    abstract::The thyroid gland is often involved in the development of neoplastic diseases, including lymphoproliferative disorders. The aim of this paper is to provide a comprehensive overview of the multiple interactions between lymphoma and thyroid. Through an extensive research among the literature, the relationship between ly...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2504

    authors: Mancuso S,Carlisi M,Napolitano M,Siragusa S

    更新日期:2018-02-27 00:00:00

  • Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.

    abstract::Among patients with advanced-stage classical Hodgkin lymphoma (cHL) receiving ABVD chemotherapy, PET performed after the first two treatment cycles (PET-2) has prognostic value. However, 15% of patients with a negative PET-2 will experience treatment failure. Here we prospectively evaluated serum thymus and activation...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2775

    authors: Viviani S,Mazzocchi A,Pavoni C,Taverna F,Rossi A,Patti C,Romano A,Trentin L,Sorasio R,Guidetti A,Gottardi D,Tarella C,Cimminiello M,Zanotti R,Farina L,Ferreri AJM,Galbiati M,Corradini P,Gianni AM,Gallamini A,Ramba

    更新日期:2020-10-01 00:00:00

  • Antisense therapy for lymphomas.

    abstract::The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1099-1069(199702)15:1<3::aid-hon583>

    authors: Cotter FE

    更新日期:1997-02-01 00:00:00

  • No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.

    abstract::This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough ) and intracellular (IMA Cintrac ) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7-4628.1 ng/ml). We found a correlation between...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2091

    authors: Racil Z,Razga F,Klamova H,Voglova J,Belohlavkova P,Malaskova L,Potesil D,Muzik J,Zackova D,Polakova KM,Zdrahal Z,Malakova J,Suttnar J,Dyr J,Mayer J

    更新日期:2014-06-01 00:00:00

  • A simple, non-invasive method of assessing the acute hemodynamic effects of doxorubicin.

    abstract::Left ventricular stroke distance was measured by Doppler ultrasound in 10 doxorubicin-treated and 10 control patients. Measurements were made 10 min, 2 h and 4 h after drug administration. Stroke distance (a linear analogue of stroke volume) increased significantly from 12.6 cm (S.D. 2.7) before and 12.5 cm (S.D. 2.7)...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900090107

    authors: Clive S,Dawson A,Bennett B,Rawles J

    更新日期:1991-01-01 00:00:00

  • Hodgkin's cell lines: characteristics and possible pathogenetic implications.

    abstract::In the last four years we established five long term cultures from tumor material of Hodgkin's disease. The in vitro cells have malignant characteristics and represent the in vivo H- and SR-cells. Common immunological, functional and morphological assays did not characterize the in vitro cells to be a known cell type ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900010204

    authors: Diehl V,Burrichter H,Schaadt M,Kirchner HH,Fonatsch C,Stein H,Gerdes J,Heit W,Ziegler A

    更新日期:1983-04-01 00:00:00

  • Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical, molecular and virological variables.

    abstract::Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese wi...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2520

    authors: Qin S,Fan L,Liang J,Gale R,Miao Y,Wu Y,Wang R,Yang H,Wu W,Xia Y,Wu J,Zhu H,Wang L,Xu W,Li J

    更新日期:2018-10-01 00:00:00

  • Cytokinetic study on the effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine on murine leukemic cells L 1210: a comparison with the effects of 1-beta-D-arabinofuranosylcytosine.

    abstract::The effects of N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) on the cell cycle of murine leukemic cells (L 1210 cells) were compared with those of 1-beta-D-arabinofuranosylcytosine (ara-C), known to be effective for acute leukemia. In a cytokinetic study, a combination of Feulgen microcytofluorometry and triti...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900030106

    authors: Maruo N,Horiuchi H,Nakabo T,Kondo M,Nakamura T

    更新日期:1985-01-01 00:00:00

  • A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.

    abstract::Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the ...

    journal_title:Hematological oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/hon.2141

    authors: Ataei S,Hadjibabaie M,Moslehi A,Taghizadeh-Ghehi M,Ashouri A,Amini E,Gholami K,Hayatshahi A,Vaezi M,Ghavamzadeh A

    更新日期:2015-06-01 00:00:00

  • Retrovirus-associated adult T-cell leukemia-lymphoma: an epidemiologic study of five cases among Hawaii-born offspring of migrant Japanese.

    abstract::Adult T-cell leukemia-lymphoma (ATLL) is a distinct clinicopathologic entity etiologically linked to HTLV-I infection. We have identified five cases of retrovirus-associated ATLL among Hawaii-born first generation offspring (nisei) of migrant Japanese. Four patients were offspring of migrant Japanese (issei) who emigr...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900070210

    authors: Yanagihara ET,Nakamura J,Kimura L,Oishi N

    更新日期:1989-03-01 00:00:00

  • Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.

    abstract::There have been some reports on a possible role of azacytidine (AZA) in the treatment of accelerated/blastic phase evolved from Philadelphia-negative myeloproliferative neoplasms (MPN-AP/BP), but results are conflicting. In this study, we analyzed a cohort of 39 patients with MPN-AP/BP treated frontline with AZA at th...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2635

    authors: Andriani A,Elli E,Trapè G,Villivà N,Fianchi L,Di Veroli A,Niscola P,Centra A,Anaclerico B,Montanaro G,Martini V,Aroldi A,Carmosino I,Voso MT,Breccia M,Montanaro M,Foà R,Latagliata R

    更新日期:2019-08-01 00:00:00

  • Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.

    abstract::Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2532

    authors: Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

    更新日期:2018-10-01 00:00:00

  • Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.

    abstract::Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2711

    authors: Apostolidis J,Mokhtar N,Al Omari R,Darweesh M,Al Hashmi H

    更新日期:2020-08-01 00:00:00

  • A review of the therapeutic agents used in the management of polycythaemia vera.

    abstract::The acquired clonal disorder Polycythaemia Vera leads to increased erythropoiesis, myelopoiesis and megakaryopoeisis. These anomalies result in an increased incidence of thromboembolic events, transformation to acute leukaemia and myelofibrosis. Treatments which aim to reduce the event rate may increase anaemia but ma...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.809

    authors: McMullin MF

    更新日期:2007-06-01 00:00:00